Etoposide
- PDF / 169,423 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 49 Downloads / 183 Views
1 S
Myelosuppression: case report A man in his 60s developed myelosuppression during treatment with etoposide for small cell lung cancer (SCLC). The 63-year-old man, who had a history of smoking (30 packs/year) and diabetes, was diagnosed with diabetic nephropathy in April 2018. Since then, he had been on haemodialysis. In February 2019, he was hospitalised for dyspnea and cough. Following examinations, he was diagnosed with limited-stage SCLC. On 23 February 2019, he started receiving oral etoposide capsule 100 mg/day on day 1 to 14, every 21 days and thoracic radiotherapy. After receiving 2 cycles, he achieved favorable radiological response. After receiving 4 cycles, he achieved partial remission. After completing 6 cycles, the disease remained stable. During the treatment process, he developed slight myelosuppression secondary to the etoposide use, which was tolerable and controllable [duration of treatment to reaction onset not stated]. Thereafter, he underwent prophylactic cranial irradiation followed by catequentinib [anlotinib] therapy for prolong progression-free survival and to avoid recurrence of the disease. Gao F, et al. Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report. Medicine 99: 803514667 No. 40, 2 Oct 2020. Available from: URL: http://doi.org/10.1097/MD.0000000000022637
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
